Hologic

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment consists of products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Hologic exceeds Q1 earnings, eyes growth in women's health

Hologic's Q1 performance surpassed expectations, driven by strong organic growth and strategic initiatives. The company's commitment to women's health, financial strength, and focus on innovation position it well for future growth. Challenges in Breast Health highlight areas for improvement, while opportunities in new markets and products offer avenues for expansion.

Hologic surpasses Q2 expectations, eyes international growth and women's health

Hologic's Q2 performance exceeded expectations, driven by robust organic revenue growth and strong margins across divisions.
While facing challenges like COVID-related revenue declines and seasonal factors, the company's strategic strengths in women's health and international expansion present growth opportunities.
To sustain growth, Hologic must navigate macro uncertainties, balance growth drivers, and capitalize on opportunities in diagnostics and global expansion.
Overall, Hologic's solid financial results, increased revenue guidance, and strategic initiatives position the company for continued success in the healthcare market.

Hologic excels in Q3 earnings, eyes global growth amid challenges

Hologic delivered strong financial results in Q3 2023, driven by robust revenue growth and strategic product offerings across its divisions.
While facing margin challenges and geopolitical uncertainties, the company remains optimistic about sustaining growth and enhancing profitability through operational improvements.
With a focus on innovation, global expansion, and cautious M&A strategies, Hologic is well-positioned to capitalize on opportunities and navigate challenges in the healthcare market.

Hologic surpasses revenue targets, eyes international growth and strategic M&A

Hologic delivered strong financial performance in Q4 2023, exceeding revenue and EPS targets while emphasizing women's health and innovation.
The company's focus on international growth, strategic capital allocation, and product portfolio strength position it well for continued success.
Challenges in regulatory compliance, M&A decisions, and market dynamics require careful navigation for sustained growth.
Opportunities in international expansion, strategic M&A, and product innovation offer avenues for future growth and market leadership.

Hologic surpasses Q1 revenue expectations, eyes international growth opportunities

Hologic delivered strong Q1 2024 results, exceeding revenue guidance and showcasing robust financial performance with organic growth of 5.2% ex-COVID.
The company's focus on innovation, market expansion, and strong customer relationships positions it well for continued growth and success beyond COVID testing.
While facing challenges such as tough comps in Q2 and potential tax rate impacts, Hologic's disciplined growth strategies and commitment to transformative initiatives offer opportunities for future expansion.
With a strong emphasis on AI capabilities, market expansion, and strategic M&A, Hologic is poised for sustained growth and market leadership in the healthcare sector.

Hologic beats Q2 revenue targets, eyes international growth opportunities

Hologic exceeded revenue and EPS expectations in Q2 2024, showcasing growth in key business segments.
While facing challenges in certain revenue streams, the company is focused on international expansion and margin improvement.
Opportunities lie in leveraging international growth, strategic acquisitions, and product utilization trends.
Overall, Hologic's performance reflects resilience post-COVID and strategic focus on innovation and market positioning.

Hologic surpasses Q3 revenue expectations, eyes international growth opportunities

Hologic's Q3 performance reflects resilience and growth across key business segments, supported by strategic investments and operational excellence. With a focus on innovation and international expansion, the company is well-positioned for sustained growth and value creation in the evolving healthcare landscape.

Hologic exceeds Q4 earnings, eyes international growth and new products

Hologic's Q4 2024 earnings call showcased strong performance, strategic strengths, and growth opportunities. Challenges include maintaining margin expansion and balancing international growth. The company's focus on durable revenue base and new product pipeline sets a positive outlook for fiscal 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Is Most-Watched Stock Hologic, Inc. (HOLX) Worth Betting on Now?

Price action for HOLX has remained stagnant for the last two years, but underlying business metrics have remained strong. Hologic has put the cash windfall from COVID to good use with recent acquisitions that can boost future growth and diversify earnings across different segments.

Hologic: An Underappreciated Gem With A Bright Future

Hologic continues to display compelling long-term value with strong FCF generation and equally as high return on investment. As an overlay of resiliency, HOLX presents with defensible characteristics for investors looking to step up in quality.

Hologic Continues To Offer Compelling Long-Term Value, Thesis Unchanged

Investors are optimistic about Hologic's (HOLX) better-than-expected results and expanded Panther installed base.

Here's Why Investors Should Retain Hologic (HOLX) Stock for Now

Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?

Hologic (HOLX) Just Reclaimed the 200-Day Moving Average

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #concerttour--Hologic and Mary J. Blige Launch “Good Morning Gorgeous” Sweepstakes as a Wake-up Call to Increase Awareness of the Importance of Preventive Care

Hologic and Mary J. Blige Launch “Good Morning Gorgeous” Sweepstakes as a Wake-up Call to Increase Awareness of the Importance of Preventive Care

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #CourtofAppeals--U.S. Court of Appeals for the Federal Circuit Affirms 2018 Ruling Barring Minerva from Challenging Hologic's Patent Rights

U.S. Court of Appeals for the Federal Circuit Affirms 2018 Ruling Barring Minerva from Challenging Hologic's Patent Rights

CARLSBAD, Calif. , July 31, 2022 /PRNewswire/ -- Active Motif Incorporated, a company with the vision of bringing epigenetics more deeply into precision medicine, announced that it has non-exclusively licensed its foundational patents in transposition for use in CUT&Tag epigenetic assays to Diagenode S.A.

Active Motif Incorporated Licenses Targeted Transposition to Diagenode S.A. Technology

Hologic (HOLX) reports better-than-expected results in the fiscal third quarter with robust sales performance in the GYN Surgical business.

Hologic (HOLX) Q3 Earnings Beat Estimates, Margins Down

Hologic, Inc. (NASDAQ:HOLX ) Q3 2022 Results Earnings Conference Call July 28, 2022 4:30 PM ET Company Participants Ryan Simon - Vice President, Investor Relations Stephen MacMillan - Chairman, President and Chief Executive Officer Karleen Oberton - Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research Tejas Savant - Morgan Stanley Patrick Donnelly - Citigroup Nisarg Shah - Bank of America Merrill Lynch Vijay Kumar - Evercore ISI Joseph Conway - Needham & Company Puneet Souda - SVB Leerink Casey Woodring - J.P. Morgan Max Masucci - Cowen and Company Ryan Zimmerman - BTIG Andrew Cooper - Raymond James Operator Good afternoon and welcome to the Hologic Third Quarter Fiscal 2022 Earnings Conference Call.

Hologic, Inc. (HOLX) CEO Stephen MacMillan on Q3 2022 Results - Earnings Call Transcript

Hologic (HOLX) delivered earnings and revenue surprises of 37.68% and 11.88%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Hologic (HOLX) Beats Q3 Earnings and Revenue Estimates

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #3QFY22--Hologic Announces Financial Results for Third Quarter of Fiscal 2022

Hologic Announces Financial Results for Third Quarter of Fiscal 2022

Align Technology

Boston Scientific

MedTech companies' results are likely to reflect a rebound in the base business. Let's see how BSX, HOLX and ALGN fare this time.

MedTech Stocks' Earnings Due on Jul 27: BSX, HOLX & ALGN

Hologic's (HOLX) Q3 performance will likely benefit from the increased utilization of Panther instruments and contributions from its recent acquisitions.

Molecular Diagnostics Sales to Drive Hologic (HOLX) Q3 Earnings

Expedia

Flex

Nexstar Media Group

PDC Energy Inc

Steel Dynamics

WillScot Mobile Mini

With the markets performing worse than they have in years, finding Nasdaq stocks trading at a discount is easier than ever. The post 7 Nasdaq Stocks Trading at a Huge Discount Right Now appeared first on InvestorPlace.

7 Nasdaq Stocks Trading at a Huge Discount Right Now

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #3DMammography--Hologic Showcases Advances across the Continuum of Breast Health at ECR 2022

Hologic Showcases Advances across the Continuum of Breast Health at ECR 2022

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #COVID--Hologic, Inc. (Nasdaq: HOLX) announced today that it is now offering its Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay and its Novodiag® RESP-4 molecular diagnostic test for sale in the European Union in time for the northern hemisphere's respiratory viral season. Both assays detect and differentiate four of the most prevalent respiratory viruses that can present with similar clinical symptoms: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), inf

Hologic Announces Two New Respiratory Assays for the Detection of COVID-19, Flu A, Flu B and RSV

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #3QFY22--Hologic to Announce Financial Results for the Third Quarter of Fiscal 2022 on Wednesday, July 27, 2022

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2022 on Wednesday, July 27, 2022

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #Fibroidawarenessmonth--New Survey Reveals Lack of Knowledge among U.S. Women about Uterine Health, Including Fibroid Symptoms and Treatment Options

New Survey Reveals Lack of Knowledge among U.S. Women about Uterine Health, Including Fibroid Symptoms and Treatment Options

Hologic's (HOLX) core molecular diagnostics franchise is growing driven by strong uptake in newer assays such as vaginitis panel and menu within the virology product line.

Hologic (HOLX) New Products Aid Growth, Margin Pressure Stays

Hologic, Inc. (NASDAQ:HOLX) is a global medical technology company that primarily focuses on improving women's health and well-being through early detection and treatment.

Why Hologic Stock is Primed for Short Sellers Right Now

Hologic presents with the economics to withstand current macroeconomic crosscurrents currently plaguing equity markets. The company's stable cash flow and free cash conversion has built a solid underweight to the investment debate.

Hologic: Unfairly Punished, Or Not? Examination Of Cash Flow And Earnings

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?

Why Is Hologic (HOLX) Up 6.7% Since Last Earnings Report?

Hologic's (HOLX) two new molecular assays monitor transplant patients for EBV and BKV.

Hologic (HOLX) Gets CE Mark for Fusion Molecular Assays

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #EpsteinBarr--Hologic Announces European CE Mark for Molecular Assays for Use with Transplant Patients

News for Hologic Stock (HOLX)